Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,707 across all filing types
Latest filing 2022-01-20 Capital/Financing Update
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a license agreement between Natco Pharma Limited and the Medicines Patent Pool. It is addressed to stock exchanges under Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure of material events. The content focuses on the licensing deal and product details, not on financial results, management changes, or regulatory filings. The document length is short (2865 characters) and it is clearly a disclosure announcement rather than a detailed report or financial statement. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to a significant business agreement impacting the company's product portfolio and market access.
2022-01-20 English
Issue of new share certificate and loss of share certificate disclsoure
Regulatory Filings
2022-01-14 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the issuance of duplicate share certificates due to loss of original certificates. It references Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content is an official notification to exchanges for record-keeping and compliance purposes. It does not contain financial data, earnings, management discussion, or any report content. It is not a report or announcement of financial results but a regulatory compliance communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-01-14 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the issuance of duplicate share certificates under SEBI regulations. It references Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, and provides details of the duplicate share certificates issued. The content is an official notification about share certificates, not a financial report, earnings release, or management discussion. It does not contain financial data or results, nor is it a report or presentation. It is a regulatory announcement related to share certificates and compliance with listing obligations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-01-14 English
NATCO Pharma Limited has been awarded Corporate Governance Award
Regulatory Filings
2022-01-07 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges referencing Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to continuous disclosures by listed companies. The content announces that NATCO Pharma Limited has been awarded a Corporate Governance Award for the year 2021. There is no financial data, no detailed report, no meeting materials, or voting results. The document is essentially an announcement of an award received, not a report or detailed filing. The length is under 5,000 characters and it is a brief announcement. Therefore, it does not fit into categories like Annual Report, Management Report, or Governance Information. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-01-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.